The year, progress was made for Ebola virus disease, genetic disorders, and the health of the planet and its population, with two new global agendas agreed. Farhat Yaqub reports.
Ebola: beginning of the end International agencies, notably WHO, were criticised over their inadequate surveillance and slow response to the Ebola outbreak in west Africa in several reports this year. Good news, however, came in July: the interim results were reported from a cluster-randomised trial of ring vaccination with a novel Ebola virus vaccine in Guinea. From 6 days after vaccination, no new cases of Ebola virus disease were diagnosed in contacts of suspected cases given immediate or delayed vaccination. Positive developments were also noted in countries: Guinea reported its last case of Ebola on Oct 29, and, on Nov 7, WHO declared that transmission had stopped in Sierra Leone. In Liberia, however, Ebola virus disease re-emerged in a cluster of three confi rmed cases in the week ending Nov 22, after WHO had declared that virus transmission had ended on Sept 3. Nepal's crises An earthquake of magnitude 7·8 struck Nepal on April 25, killing more than 8700 people and injuring more than 22 300. 2 weeks later, on May 12, another earthquake of 7·3 magnitude occurred. An estimated 8 million people (about a third of Nepal's population) were affected by the earthquakes and more than 300 aftershocks. More than 160 000 homes were destroyed and vital infrastructure was severely damaged; 765 health facilities needed to be reconstructed after the earthquakes. Nepal faced another humanitarian crisis at the end of the year with a blockade at its border with India that caused severe shortages of fuel, food, and medicines. As The Lancet went to press, the blockade was still in place. Greek tragedy Greece's financial crisis and imposed austerity measures continued to harm its health system and the health of its people. Only 4% of the gross domestic product is expected to be spent on health care this year, compared with 10% in 2009. 2·5 million of 11 million people in the country are unemployed and do not have health-care coverage. There are severe shortages of medical staff and medicines, including insulin and drugs for cancer. Screening for some cancers has also been reduced. Rates of depression, suicide attempts, and death by suicide in adults have increased. (GFF) . The GFF is a fi nancing platform to support the UN Secretary-General's Global Strategy for Women's, Children's and Adolescents' Health and the Sustainable Development Goals. The goal of the partners of the GFF is to support 62 high-burden lowincome and lower-middle-income countries. During the next 5 years, US$12 billion will be used from domestic, international, private, and public resources for the health of women, children, and adolescents in the fi rst round of countries to benefi t from the GFF: Democratic Republic of the Congo, Ethiopia, Kenya, and Tanzania.
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Cystic fibrosis Two very different, promising treatments for patients with cystic fi brosis were reported this year. Pooled analyses of 1108 patients who were homozygous for Phe508del (the most common CFTR mutation) in the TRANSPORT and TRAFFIC randomised, placebo-controlled trials in Australia, Europe, and the USA, showed that the combination of lumacaftor and ivacaftor at all doses tested significantly improved the mean absolute change from baseline in the percentage predicted forced expiratory volume in 1 s (FEV₁) at 24 weeks. On July 2, the US Food and Drug Administration approved the combination treatment lumacaftor 200 mg plus ivacaftor 125 mg (Orkambi, Vertex Pharmaceuticals, Cambridge, MA, USA). However, the high cost of the treatment-US$259 000 per yearhas been criticised. Gene therapy for cystic fi brosis was also in the news. In a randomised, phase 2b study in the UK in patients with any combination of CFTR mutations, repeated nebulisation with non-viral CFTR gene-liposome complex pGM169/GL67A slightly improved the change in percentage predicted FEV₁ versus placebo at the 12-month follow-up.
Vaccine roll-out In March, after long negotiations between the UK Government and Glaxo-SmithKline about the costs of the meningitis B vaccine (Bexsero), the Health Secretary Jeremy Hunt announced plans to roll out meningitis B vaccinations for babies. Since September, parents have been offered meningitis B vaccination for their babies if born on or after July 1, as part of a routine National Health Service (NHS) programme. The vaccine is recommended for babies aged 2 months, with a second dose at age 4 months, and a booster dose at age 12-13 months. It has also been offered on the NHS to parents for children born on or after May 1, as a one-off catch up.
Three-person IVF Mitochondria were in the spotlight this year. In the UK, a new law for mitochondrial replacement (three-person in-vitro fertilisation) came into effect on Oct 29, after the House of Commons and the House of Lords voted in favour of it. Mitochondrial replacement will only be allowed for the avoidance of serious mitochondrial diseases in children. Meanwhile, in the USA, investigators reported the generation of genetically corrected pluripotent stem cells from patients with common heteroplasmic mutations implicated in mitochondrial diseases. 
Global agreements
Meaty issue
One health story received widespread coverage-and criticism. On Oct 26, WHO's International Agency for Research on Cancer (IARC) Monograph Working Group reported some of the results of its assessments of the carcinogenicity of processed meat. According to the group's fi ndings, processed meat was classifi ed as "carcinogenic to humans" (IARC group 1) based on evidence from studies linking consumption of 50 g/day with an 18% increase (95% CI 1·10-1·28) in the risk of colorectal cancer. Also, a positive association was noted between the consumption of processed meat and stomach cancer. However, the classifi cation received criticism because it put processed meat in the same IARC group as formaldehyde, tobacco, and all forms of asbestos. Also, the working group only reviewed existing evidence and did not gather new evidence. Some researchers have called for a retraction of the results.
Polio worldwide Europe reported its first cases of polio since 2010. On Sept 1, Ukraine reported two cases of circulating vaccine-derived poliovirus in children aged 10 months and 4 years in Zakarpatskaya oblast. Because of the low coverage with the polio vaccine in Ukraine, the risk of transmission was high. After a delay that was criticised by WHO, in October, Ukraine began a response to the outbreak and, as of Nov 7, more than 1 million of more than 2 million children younger than 6 years old have been given the fi rst dose of the polio vaccine. On Sept 25, WHO announced that Nigeria was not endemic for wild poliovirus type 1; the country has not reported any cases since July 24, 2014. Only Afghanistan and Pakistan remain endemic for polio.
Farhat Yaqub
For the TRANSPORT and TRAFFIC trials see N Engl J Med 2015; 373: 220-31 
